At EVQLV, we solve the multi-billion dollar problem of antibody discovery failure. We use AI to replicate the process of how antibodies become drugs for biotechs and pharmaceutical companies. They pay us upfront to supply them with AI-generated antibody sequences, then pay annual license fees the sequences while they produce/test the antibodies. And when they find an antibody they like, they pay us again to acquire the rights to the sequence.